disease, Crohn's disease, and cancer. Despite considerable research, none of these inhibitors are available for clinical application. Herein, we designed and synthesized novel thienopyrimidine derivatives by a bioisosteric replacement and investigated their structure–activity relationships. Thieno[3,2-d]pyrimidine derivative 22 showed the most potent inhibitory activity and inhibited both wild-type and
富含亮
氨酸的重复激酶 2 (LRRK2) 被认为是帕
金森病、克罗恩病和癌症的有希望的治疗靶点。尽管进行了大量研究,但这些
抑制剂中没有一种可用于临床应用。在此,我们通过
生物等排取代设计和合成了新型
噻吩并
嘧啶衍
生物,并研究了它们的构效关系。Thieno[3,2- d ]
嘧啶衍
生物22显示出最有效的抑制活性,并抑制野生型和 G2019S 突变体 LRRK2,IC 50值分别为 30 和 14 nM。